TUBORG BOULEVARD 12, HELLERUP, G7
Announces Week 52 Data from the reACHin Trial Showing Treatment Benefits in Infants with Achondroplasia
Grants 29,380 Warrants to Employees
Enters Binding Term Sheet for Global Settlement and License Agreement with BioMarin Pharmaceutical Inc.
Reports Second Quarter 2026 Financial Results
Reports Financial Results for the Period Ended June 30, 2026
Grants 15,060 Warrants to Employees
Provides Updates on Achondroplasia Programs
Grants 14,060 Warrants to Employees
Annual and Transition Report of Foreign Private Issuers
Amended Registration of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Amended Initial Statement of Beneficial Ownership
Specialized Disclosure Report